Purchase this article with an account.
G. Besozzi, F. Boscia, L. Sborgia, C. Furino, N. Cardascia, R. Dammacco, G. Sborgia, A. Ferrara, C. Sborgia; Intravitreal Ranibizumab and Low Fluence Photodynamic Therapy to Treat Choroidal Neovascularization Due to Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2009;50(13):5223. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate efficacy and safety of intravitreal ranibizumab (IVR) and low fluence photodynamic therapy (LFPDT) protocol to treat choroideal neovascularization due to age-related macular degeneration (AMD-CNV)
twenty-three eyes with AMD-CNV (12 naïve and 11 already treated with standard PDT) underwent combined treatment with 0.03 mg IVR (1/month for 3 months) and LFPDT (parameters reduced to 25mJ/cm2, 300mW/cm2, with standard dose of verteporfin and timing) after 5-14 days. Best corrected visual acuity (BCVA) was measured using ETDRS charts; biomicroscopy, fluorescein angiography (FA), and optical coherence tomography (OCT) were performed, in order to evaluate functional and anatomical outcomes
Mean follow-up was 8.6±2.2 months (range: 5-15). BCVA was improved in all patients and also in subgroups analysis (p>0.05). No patient experienced severe visual loss. No patient showed FA leakage. OCT demonstrated neuroretinal detachement resolution in 20/23 (87%) ad RPE detachment resolution in 9/15 (60%). Three eyes (13%) had IVR+LFPDT single retreatment. No complication were observed.
combined IVR+LFPDT therapy is safe and effective in AMD-CNV, improving visual acuity and anatomical conditions. Further controlled study is warranted to demonstrate the long term efficacy and safety of this treatment option.
This PDF is available to Subscribers Only